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Abstract
Introduction: The motor system is selectively vulnerable to mutations in the ubiquitously expressed aggregation-
prone enzyme superoxide dismutase-1 (SOD1).
Results: Autophagy clears aggregates, and factors involved in the process were analyzed in multiple areas of the
CNS from human control subjects (n = 10) and amyotrophic lateral sclerosis (ALS) patients (n = 18) with or without
SOD1 mutations. In control subjects, the key regulatory protein Beclin 1 and downstream factors were remarkably
scarce in spinal motor areas. In ALS patients, there was evidence of moderate autophagy activation and also
dysregulation. These changes were largest in SOD1 mutation carriers. To explore consequences of low autophagy
capacity, effects of a heterozygous deletion of Beclin 1 were examined in ALS mouse models expressing mutant
SOD1s. This caused earlier SOD1 aggregation, onset of symptoms, motor neuron loss, and a markedly shortened
survival. In contrast, the levels of soluble misfolded SOD1 species were reduced.
Conclusions: The findings suggest that an inherent low autophagy capacity might cause the vulnerability of the
motor system, and that SOD1 aggregation plays a crucial role in the pathogenesis.
Keywords: Amyotrophic lateral sclerosis, Autophagy, Motor system vulnerability, Protein aggregates, Superoxide
disumutase-1
Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neuro-
degenerative disorder characterized by loss of the upper and
lower motor neurons. The disease begins focally and then
spreads contiguously, resulting in progressive paralysis and
finally death from respiratory failure [45]. Next to C9orf72
[15], the most common known cause of ALS is mutations
in the gene of the antioxidant enzyme superoxide
dismutase-1 (SOD1), which are found in 2.5–6 % of the
cases [1]. SOD1 is ubiquitously expressed, and the cause of
the selective vulnerability of the motor system is not
understood [30]. Over 180 mutations in SOD1 have been
identified in ALS patients (http://alsod.iop.kcl.ac.uk/) [53].
They confer a cytotoxic gain of function to the enzyme,
which is also poorly understood. Several of the mutations
cause long C-terminal truncations or other disruptive
changes in the expressed protein, precluding native fold-
ing. This suggests that any cytotoxicity mechanism that is
common to the SOD1 mutants would originate from mis-
folded SOD1 species.
Inclusions containing aggregated SOD1 are hallmarks of
ALS, both in patients and in transgenic animal models ex-
pressing mutant human SOD1s (hSOD1) [31]. This fits with
a noxious role of hSOD1 un/misfolding, which allows for-
mation of the non-native contacts present in aggregated
species [34]. However, it is currently unknown whether the
hSOD1 aggregation drives the pathogenesis of ALS, whether
it is harmless, and even whether it represents protective
scavenging of more toxic soluble misfolded species when
the proteostasis is terminally compromised.
Macroautophagy, hereafter called autophagy, is the princi-
pal pathway by which cellular protein aggregates are cleared
[12]. To gain further insight into the role of aggregation in
ALS, we examined autophagy factors in several areas of the
CNS in patients and in non-neurological controls and con-
trols with neurodegeneration. We found remarkably low
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content of the key autophagy regulator Beclin 1 and down-
stream factors in the motor area of spinal ventral horns in
the controls, and we also found evidence for activation of
autophagy and dysregulation in ALS patients. To investigate
the consequences of a low autophagy capacity, the effects of
a heterozygous deletion of the Becn1 gene were tested in
hSOD1 transgenic mouse models with characteristics re-
sembling ALS in humans. This caused earlier hSOD1 aggre-
gation, onset of symptoms, and motor neuron loss, and also
markedly shortened survival. However, there were reduced
levels of soluble misfolded hSOD1 species, suggesting that
aggregation could be the prime driver of neurotoxicity.
Materials and methods
Human subjects
The human study was performed according to the tenets
of the Declaration of Helsinki. The collection of human
tissues and their use was approved by the Swedish
Medical Ethical Review Board. After informed consent
from the relatives and whenever possible from the pa-
tients, specimens of CNS gray matter, including tem-
poral lobe (ventral 3rd of temporal superior gyrus),
frontal lobe (anterior cingulate gyrus), cerebellar vermis,
precentral gyrus (hemisphere close to the medial border),
and spinal cord, were obtained at autopsy. The dissected
segments of the spinal cord included the lamina IX of the
ventral horn and the dorsal horn at the cervical or lumbar
levels. Altogether, 28 human subjects were examined: five
non-neurological controls (mean age at death: 60 ± 14
[SD] years, range 43–80 years), five Parkinson’s disease
(PD) patients (77 ± 6 years, range 67–82) , four sporadic
ALS (SALS) patients (70 ± 10 years, range 62–83), five
familial ALS (FALS) patients without SOD1 mutations
(58 ± 8 years, range 49–68) including four patients with
Table 1 Information on humans subjects used in this study
Case Diagnosis Sex Gene mutation Age at death (years) Postmortem delay (hours)
1 Controls M None 43 N.A.
2 Controls F None 80 48
3 Controls F None 64 42
4 Controls M None 55 48-72
5 Controls M None 58 29
6 SALS F None 69 44
7 SALS F None 83 48-72
8 SALS F None 62 52
9 SALS F None 64 24
10 FALS M C9orf72 49 23
11 FALS M Not found 64 48-72
12 FALS M C9orf72 52 20
13 FALS F C9orf72 55 13
14 FALS M C9orf72 68 50
15 FALS F SOD1 A4V 62 N.A.
16 FALS F SOD1 G72C 73 N.A.
17 FALS M SOD1 D90A 75 29
18 FALS F SOD1 D90A 64 50
19 FALS M SOD1 D90A 43 32
20 FALS M SOD1 D90A 53 11
21 FALS M SOD1 D90A 66 56
22 FALS F SOD1 G127X 62 20
23 FALS M SOD1 G127X 44 36-50
24 PD M N.A. 67 52
25 PD F N.A. 82 72-96
26 PD F N.A. 80 8
27 PD M N.A. 81 72
28 PD F N.A. 76 N.A.
SALS sporadic ALS, FALS familial ALS, PD Parkinson’s disease, M male, F female, N.A. not available
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expanded hexanucleotide GGGGCC repeats in C9orf72,
and nine FALS patients with SOD1 mutations (60 ±
11 years, range 43–75) including one A4V [2], one G72C
[48], five D90A [30], and two G127instggg (G127X) [27, 28].
None of the five ALS patients without SOD1 or C9orf72
mutations carried ALS-associated mutations: all tested
negative for a panel of ALS-associated genes including
ANG, FUS, OPTN, SQSTM1/p62, TARDBP, TBK1,
UBQLN2, or VAPB. All ALS patients fulfilled the revised
El Escorial criteria for clinically definite or probable ALS
[10]. The postmortem time for all patients varied between
0 and 3 days, and there were no systematic differences
among the groups (Table 1).
The CNS tissues were extracted as described previ-
ously [17, 30]. For analysis of the CNS expression pat-
terns of autophagy factors, temporal lobe (ventral 3rd of
temporal superior gyrus) from a non-neurological con-
trol (case 4, Table 1) was used as a standard to allow
multiple comparisons between different gels.
Generation and analyses of ALS model mice with
impaired autophagy
As mouse models of ALS, we used two distinct lines of
transgenic mice carrying mutant human SOD1s:
hSOD1G127X [28] and hSOD1G93A [23]. The
hSOD1G127X mice were generated in our laboratory
(line 716), whereas the hSOD1G93A mice were pur-
chased from Jackson Laboratories (strain name: B6SJL-
Tg(SOD1-G93A)1Gur/J; stock number: 002726). Both
lines were back-crossed into a C57BL/6 J background
for more than 30 generations.
The mouse strain with a heterozygous deletion of
Becn1 was kindly provided by Professor Beth Levine
[44]. The Becn1+/- mice were maintained in a CBA back-
ground. Male hSOD1G127X or hSOD1G93A mice were
crossed with female Becn1+/- mice. The genotype of the
offspring was determined using PCR as described previ-
ously [44]. To avoid effects of different genetic back-
grounds, non-transgenic and single-mutant mice from
the litters were used for comparison with the double-
mutant mice.
All animal procedures were carried out according to
the guidelines of the Animal Care and Use Committee
of the Umeå University. The animal protocols were
approved by the Umeå Ethical Committee on Animal
Experiments.
Phenotyping of the mice
The disease courses of the mice were evaluated according
to criteria based on changes in body weight [6]. Disease
onset was regarded as the time when each mouse reached
its peak weight. The endpoint was defined as the age at
which a mouse was unable to right itself within 5 s after
being pushed onto its side. The duration of disease was
regarded as the period from onset of disease until the
endpoint.
The hSOD1G127X/Becn1+/- mice and their littermates
were analyzed at three distinct stages of the disease: a
presymptomatic stage (150 days), a symptomatic stage
(10 % weight loss), and a terminal stage (n = 5 per geno-
type per disease stage). The hSOD1G93A/Becn1+/- mice
and their littermates were examined at a symptomatic
stage (10 % weight loss) and a terminal stage (n = 4 per
genotype per disease stage). The lumbar half of the
spinal cord was immediately dissected, frozen in liquid
nitrogen, and stored at −80 °C until use. The spinal
cords of mice were extracted in phosphate-buffered sa-
line (pH 7.0) containing 1 % (v/v) Nonidet P-40 and
EDTA-free Complete® protease inhibitor cocktail (Roche
Applied Science) as described previously [51], yielding
detergent-soluble and insoluble fractions.
Western immunoblot
Tissue extracts (20 μg protein) were electrophoresed on
Criterion® TGX gels (Any kD; Bio-Rad), and were blotted
onto polyvinylidene difluoride membranes (GE Health-
care). The blots were incubated with the following primary
antibodies: anti-Beclin 1 (1:10,000; #3495; Cell Signaling
Technology), anti-autophagy related gene (Atg) 12 (1:5,000;
#4180; Cell Signaling Technology), anti- microtubule-
associated protein light chain 3 (LC3) (1:10,000; PM036;
Medical & Biological Laboratories), anti-p62 (1:2,000;
610832; BD Biosciences), anti-lysosome associated mem-
brane protein 2 (Lamp2) (1:10,000; PA1-655; Thermo
Scientific), anti-Cathepsin D (1:20,000; ab6313, Abcam),
anti-glucose-regulated protein 78 kDa (Grp78) (1:10,000;
NB100-91794; Norvus Biologicals), and anti-C/EBP hom-
ologous protein (Chop) (1:2,500; sc-575; Santa Cruz
(See figure on previous page.)
Fig. 1 Autophagy factors are present in exceptionally low amounts in spinal ventral horns of human controls. a, b Western blots for autophagic proteins
in human postmortem specimens of distinct CNS regions from (a) non-neurological and (b) neurodegenerative (Parkinson’s disease; PD) controls. Aliquots
of protein extracts (20 μg) were loaded in each well. β-Actin was used as a loading marker. To allow multiple comparisons between different gels, grey
matter from the anterior 3rd of the temporal superior gyrus from a non-neurological control was used as a standard. Triplicate analyses of the proteins were
made. Analysis of multiple triplicates indicated a relative standard deviation of the estimates of around 7 %. c–f Scatter plots showing the expression
patterns of autophagic proteins including (c) Beclin 1, (d) Atg12 (detected as Atg12-Atg5 complex), (e) LC3-II, and (f) p62. All values in each CNS region
were normalized to the level of expression of the standard. Bars represent mean values. *P< 0.05 vs. ventral horn of non-neurological controls. **P< 0.01
vs. ventral horn of non-neurological controls. ##P< 0.01 vs. ventral horn of PD (one-way ANOVA with Tukey-Kramer’s test.)
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Biotechnology). β-Actin (1:50,000; MAB1501R; Millipore)
was used as a loading control. For SOD1 analysis, we used
anti-hSOD1G127X (0.01 μg/mL) [28], anti-hSOD1
(0.001 μg/mL; human-specific, raised against a peptide cor-
responding to amino acids 24–39 of hSOD1) [17], or anti-
murine SOD1 antibodies (0.1 μg/mL, raised against a pep-
tide corresponding to amino acids 24–36 in murine SOD1)
[29]. As secondary antibody, horseradish peroxidase-
conjugated anti-rabbit or anti-mouse IgG (1:25,000; Dako)
was used. The immunoreaction was visualized using an
ECL Select reagent (GE Healthcare). The chemilumines-
cence of the blots was quantified using Quantity One soft-
ware (Bio-Rad).
Quantification of insoluble ubiquitinated proteins
Equal volumes of the detergent-insoluble fractions
were separated on 4–15 % Criterion® TGX gels (Bio-
Rad) and analyzed using western blot with anti-
ubiquitin antibody (1:25,000; Z0458; Dako), which
reacts with both Lys48- and Lys63-linked chains [50].
β-Actin in whole homogenates (1:50,000; MAB1501R;
Millipore) was used as an internal marker.
Analysis of hSOD1 aggregates using a filter trap assay
Amounts of large hSOD1 aggregates in the lumbar half
of the spinal cords were quantified using a filter trap
assay as described previously [5]. The following primary
antibodies were used: anti-hSOD1G127X (0.03 μg/mL)
[28] and anti-hSOD1 (0.03 μg/ml; raised against a pep-
tide corresponding to amino acids 57–72 of hSOD1)
[17]. The aggregate standard (=100 %) was a homogenate
of a spinal cord of a terminally ill hSOD1G93A mouse kept
in multiple aliquots in a freezer. The intensity of the stain-
ing of the tissue homogenates were related to staining of
this standard keeping track of the dilutions used.
Histopathology
Mice were perfused transcardially with saline followed
by 4 % (w/v) paraformaldehyde in saline (pH 7.4). The
lumbar spinal cords were harvested and embedded in
paraffin. The lumbar sections (6 μm thickness) were im-
munostained with the following primary antibodies:
anti-hSOD1G127X (0.1 μg/mL) [28], anti- glial fibrillary
acidic protein (GFAP) cocktail (0.01 μg/mL; 556330; BD
Biosciences), and anti- ionized calcium-binding adapter
molecule 1 (Iba1) (0.05 μg/mL; 019-19741; Wako Pure
Chemicals). The sections were incubated with biotinyl-
ated secondary antibody against rabbit IgG or mouse
IgG (1:200; Vector Laboratories). The immunoreaction
was amplified using the VECTASTAIN® ABC Kit (Vector
Laboratories) and was detected using 3,3’-diaminobenzi-
dine (Dako) as the chromogen. The sections were im-
aged using a Pannoramic 250 Flash II scanner (3D
Histech Ltd.).
Counting of α-motor neurons was performed as de-
scribed previously [22], with slight revision. Serial trans-
verse sections of the lumbar region were cut with a slice
thickness of 6 μm. To avoid repeated counting of the
same α-motor neuron, every tenth lumbar section of the
spinal cord (L1–L3) was immunostained with anti-NeuN
antibody (1 μg/mL; MAB377; Millipore), which does not
recognize γ-motor neurons [19]. The size of the soma of
NeuN-positive neurons was measured using Pannoramic
Viewer software (3D Histech Ltd.). The number of α-
motor neurons (>400 μm2) in the ventral horn was
counted in 10 sections per mouse (n = 3–5 per
genotype).
Measurement of proteasome activities
The chymotrypsin-like, trypsin-like, and caspase-like ac-
tivities of proteasome were measured as described else-
where [49] using a Proteasome-Glo™ Cell-Based Assay
Kit (Promega). Background non-specific peptidase activ-
ities were determined by adding proteasome inhibitors:
bortezomib (0.1 μg/mL for chymotrypsin-like activity;
Calbiochem) or AdaAhx3L3VS (30 μg/mL for trypsin-
like and caspase-like activities; Calbiochem). The prote-
asome activities were calculated by subtracting the
values with the inhibitors (non-specific peptidase) from
the values without the inhibitors (total peptidase).
Statistics
All data are given as mean ± SD. All statistical tests were
performed with Statcel 3 software (OMS Publishing Inc.).
Temporal changes in body weight of mice were analyzed
using repeated-measures ANOVA. The disease onset and
survival of mice were compared using Kaplan-Meier ana-
lysis with log-rank test. After validation of data normality
(See figure on previous page.)
Fig. 2 Autophagy factors become elevated in the spinal ventral horns and precentral gyrus of ALS patients. a, b Western blots for autophagic
proteins in human postmortem specimens of (a) spinal ventral horns and (b) precentral gyrus from five non-neurological controls, four SALS
patients, five FALS patients without SOD1 mutations including expanded hexanucleotide GGGGCC repeats in C9orf72 (n = 4), and nine FALS
patients with SOD1 mutations including one A4V, one G72C, five D90A, and two G127X. Aliquots of protein extracts (20 μg) were loaded in each
well. β-Actin was used as a loading marker. c–j Scatter plots showing the expression levels of autophagic proteins in (c–f) ventral horn and (g–j)
precentral gyrus. All values in each CNS region were normalized to the level of expression of the temporal lobe standard. Bars represent mean
values. *P < 0.05 vs. controls. **P < 0.01 vs. controls. N.S. not significant (vs. controls). Statistical analysis was performed using one-way ANOVA with
Tukey-Kramer’s test
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and homoscedasticity, the disease duration was analyzed
using a two-tailed Welch’s t-test. Multiple group compari-
sons were performed using one-way ANOVA followed by
Tukey-Kramer post-hoc test. Statistical significance was
defined as P < 0.05. The “n” values indicate numbers of in-
dividual humans or animals but not replicate measures of
one sample. All biochemical and histopathological studies
were replicated at least twice to validate the findings.
Results
Exceptionally low concentrations of autophagy factors in
human spinal ventral horns
Autophagy factors were analyzed in several areas of the
CNS of controls and ALS patients with or without SOD1
mutations. In non-neurological controls, Beclin 1, the
principal initiator of autophagy [12], was found to be
exceptionally low in lamina IX of the spinal ventral horns
as compared to other gray-matter areas of the CNS
(Fig. 1a, c). The ventral horn concentrations were equally
low in PD patients, a neurodegenerative condition not af-
fecting this area (Fig 1b, c). The levels of the downstream
autophagy factors the Atg12-Atg5 complex, the LC3-II,
and p62 were also low in the ventral horns of the controls
(Fig. 1d, e, f ), suggesting a low degree of basal autophagy
activity.
In ALS patients, the levels of Beclin 1, Atg12-Atg5,
and p62 were modestly elevated, more so in carriers of
SOD1 mutations than in apparently sporadic patients
and carriers of other ALS-linked mutations (Fig. 2a, c,
d, f ). However, the concentrations only approached
those found in other areas of the CNS in the control
groups (Fig. 1). There were no changes in LC3-II (Fig. 2e).
The primary motor cortex in the precentral gyrus, another
area affected in ALS, also showed increases in Beclin 1
and p62 expression (Fig. 2b, g, j). The Atg12-Atg5 levels
were significantly elevated in SALS and carriers of SOD1
mutations, but not in FALS without SOD1 mutations
(Fig. 2h). Again, no changes were found in LC3-II (Fig. 2i).
Notably, in the case of the precentral gyrus, the changes
were comparatively moderate in carriers of SOD1
mutations.
The autophagy factors were similarly analyzed in
spinal dorsal horns, temporal and frontal lobe gray mat-
ter, and cerebellar vermis, but in these areas there were
no differences between the controls and the ALS groups
(Additional file 1: Figure S1).
Heterozygous deletion of Becn1 in hSOD1G127X mice
exacerbated ALS-like disease
To explore the consequence of low autophagy capacity
on hSOD1-induced motor neuron disease, the effects of
heterozygous deletion of the Becn1 gene were tested in
mice expressing mutant hSOD1s. Homozygous deletion
of Becn1 leads to early embryonic lethality, whereas mice
with a heterozygous deletion are essentially normal but
show impaired autophagy [41, 44]. As our principal
model, we chose mice expressing the truncated mutant
hSOD1G127X since it offers several advantages. All of this
mutant hSOD1 exists as potentially toxic misfolded
monomers in the CNS [54, 55]. The levels of such spe-
cies can therefore be directly measured without con-
founding by the natively folded hSOD1 present in most
other transgenic models [29, 54, 55]. Owing to rapid tar-
geting for degradation, the hSOD1G127X concentrations
are low, less than one-half of those of the endogenous
murine SOD1, minimizing the risk of overexpression arti-
facts [4, 28, 29]. Finally, mimicking ALS in humans, there
is a long symptom-free period followed by a middle age
onset and a relatively rapid disease course (Fig. 3i).
We verified that activation of autophagy occurred in
hSOD1G127X mice by analysis of autophagy and lyso-
some factors (Additional file 2: Figure S2). There were
no changes in Beclin 1 and Atg12-Atg5, but there were
significant increases in LC3-II, p62, Lamp2, and Cathepsin
D already at 150 days, i.e. before onset of symptoms, and
further increases at the symptomatic and terminal stages.
This is similar to what has been found in other ALS
models [25, 56]. In humans, there were also increases in
Beclin-1 and Atg12-Atg5, but not LC3-II, suggesting the
existence of some species differences in the autophagic re-
sponse to SOD1-provoked ALS (Fig. 2c–f ). Still, the re-
sults suggested that manipulation of autophagy in the
mice might give information on the role of the system in
aggregate clearance and on the neurotoxic role of the
aggregates.
Male hSOD1G127X mice were crossed with female mice
with a heterozygous deletion of Becn1. In the resulting
litters, as expected, the Becn1 deletion halved the levels
(See figure on previous page.)
Fig. 3 Heterozygous deletion of Becn1 impairs autophagy and exacerbates the disease course in hSOD1G127X mice. a Western blots for autophagic and
lysosomal proteins in the spinal cords of hSOD1G127X/Becn1+/- mice and littermates (n= 3 per genotype). b–g The relative expression levels of (b) Beclin 1,
(c) Atg12-Atg5, (d) LC3-II, (e) p62, (f) Lamp2, and (g) Cathepsin D in terminally ill mice. Data are given as mean ± SD. *P< 0.05 vs Non-Tg. **P< 0.01 vs
Non-Tg. ##P< 0.01 vs. hSOD1G127X (one-way ANOVA with Tukey-Kramer’s test). N.S. not significant (vs. Non-Tg). h–j The disease courses of hSOD1G127X mice
(n= 13; male:female 7:6) and hSOD1G127X/Becn1+/- mice (n= 14; male:female 7:7) were evaluated based on alterations in body weight. h Temporal changes
in body weight of the mice. Statistical significance was analyzed using repeated-measures ANOVA. i Kaplan-Meier curves for disease onset and survival.
Statistical significance was analyzed using repeated-measures ANOVA using Kaplan-Meier analysis with log-rank test. j Scatter plot for the disease duration.
Bars represent mean values. **P< 0.01 (two-tailed Welch’s t-test)
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of Beclin 1 regardless of the hSOD1G127X transgene
(Fig. 3a, b). Although the level of Atg12-Atg5 was not al-
tered (Fig. 3c), there was a 40 % reduction in LC3-II
concentration and a 42 % increase in p62 concentration
(Fig. 3d, e), suggesting that the reduction in Beclin 1 sig-
nificantly impaired the autophagic flux in the spinal
cords. Additionally, we found that the expression of lyso-
somal markers, Lamp2 and Cathepsin D, was increased in
terminally ill hSOD1G127X mice, but less so in
hSOD1G127X/Becn1+/- mice (Fig. 3f, g). A blocking effect
of mutant hSOD1 on maturation of autophagolysosomes
might conceivably also have contributed to the patterns
observed.
The disease courses of the resulting hSOD1G127X/
Becn1+/- mice and hSOD1G127X mice were monitored
(Fig. 3h-j). Time of onset occurred 53 days earlier in
hSOD1G127X/Becn1+/- mice than in hSOD1G127X mice
(295 ± 19 vs. 348 ± 13 days; P = 5.1 × 10-6) (Fig. 3i). The
disease duration was 38 days shorter (30 ± 4.4 days vs.
68 ± 13 days; P = 7.1 × 10-10) (Fig. 3j), and the
hSOD1G127X/Becn1+/- mice reached the end stage
90 days earlier than the hSOD1G127X mice (326 ± 19 days
vs. 416 ± 19 days; P = 3.0 × 10-6) (Fig. 3i).
Motor neurons were counted throughout the course of
disease (Fig. 4a, b). Earlier and more extensive loss was
found in hSOD1G127X/Becn1+/- mice than in hSOD1G127X
mice at the symptomatic stage (43 ± 3.3 % in hSOD1G127X
vs. 70 ± 3.8 % in hSOD1G127X/Becn1+/-, P < 0.01) and at the
terminal stage (57 ± 4.6 % vs. 87 ± 4.3 %, P < 0.01). In non-
transgenic and Becn1+/- mice, no changes in motor neuron
count were seen. The more extensive motor neuron loss in
hSOD1G127X/Becn1+/- mice was accompanied by enhanced
numbers and activation of astrocytes and microglia at the
symptomatic and terminal phases (Fig. 4c, d).
Thus, deletion of even a single allele of Becn1 in
hSOD1G127X mice results in exacerbation of the disease
course―including onset, duration, lifespan, and loss of
spinal motor neurons.
Since Beclin 1 is a haplo-insufficient tumor suppressor
gene, Becn1+/- mice develop tumors in several tissues in-
cluding the lungs and liver when over 400 days old.
These can be detected even by gross morphology [44].
To exclude the possibility that exacerbation of the dis-
ease course in hSOD1G127X/Becn1+/- mice was associ-
ated with development of tumors, we examined the
gross appearance of lungs and liver from terminally ill
hSOD1G127X/Becn1+/- mice, age-matched Becn1+/- mice
and non-transgenic mice (Additional file 3: Figure S3a).
No changes were found. The rise in body weight in
Becn1+/- mice (n = 8; male:female 4:4) was essentially
identical to that in non-transgenic mice (n = 10; male:-
female 4:6), at least until 320 days of age (P = 0.56),
which was the mean lifespan of hSOD1G127X/Becn1+/-
mice (Additional file 3: Figure S3b).
Heterozygous deletion of Becn1 in hSOD1G127X mice
increased aggregated and decreased soluble mutant
hSOD1
The total concentration of hSOD1G127X in spinal cords
rose with time; at all ages, it was higher in hSOD1G127X/
Becn1+/- mice than in hSOD1G127X mice (Fig. 5a, b).
This was caused by increased levels of detergent-
insoluble hSOD1G127X (Fig. 5c), which were higher in
hSOD1G127X/Becn1+/- mice than in hSOD1G127X mice.
Even when compared at the same disease stages, the
concentrations were higher in hSOD1G127X/Becn1+/-
mice: 2.0-fold and 1.6-fold at the symptomatic and ter-
minal stages, respectively. In contrast, the concentra-
tions of soluble hSOD1G127X declined with time and at
all stages they were lower in hSOD1G127X/Becn1+/- mice
than in hSOD1G127X mice (Fig. 5d). As an independent
method for analysis of hSOD1 aggregates, the spinal
cord homogenates were analyzed with a dot-blot filter
assay (Fig. 5e). The time-course patterns were very simi-
lar to those of the detergent-insoluble hSOD1G127X
species.
The hSOD1G127X mutant in lumbar spinal cords was
also examined by immunohistochemistry (Fig. 5f). At the
presymptomatic stage, the highest levels of the protein
were seen in the vulnerable α-motor neurons of the
ventral horn. Other cell populations were more faintly
stained. At the symptomatic and terminal stages, punctate
aggregates also accumulated in the neuropil. The levels
were clearly higher in the hSOD1G127X/Becn1+/- mice.
To test the possibility that the drastic alterations in
hSOD1G127X fractions might to any degree be caused by
changes in SOD1 synthesis in the compromised spinal
cord, the endogenous murine SOD1 was analyzed with a
mouse-specific antibody (Additional file 4: Figure S4).
No changes in concentration were found and it was sol-
uble: detergent-insoluble/aggregated murine SOD1 could
not be demonstrated at any of the disease stages. This is
(See figure on previous page.)
Fig. 4 Impaired autophagy worsens ALS-related pathological changes in spinal cords of hSOD1G127X mice. The hSOD1G127X/Becn1+/- mice and littermates
were analyzed at three distinct stages of the disease: a presymptomatic (150 days), a symptomatic (10 % weight loss), and the terminal stage. The lumbar
spinal cord sections were immunostained with antibodies against (a) NeuN, (c) GFAP, or (d) Iba1, which are specific markers for neurons, astrocytes, or
microglia, respectively. We used 320-day-old non-transgenic (Non-Tg) and Becn1+/- mice. b Quantification of NeuN-positive α-motor neurons in the lumbar
spinal cords (n= 3–5 per genotype). **P< 0.01 vs. disease stage-matched hSOD1G127X. N.S. not significant vs. 150-day-old hSOD1G127X (one-way ANOVA
with Tukey-Kramer post-hoc test.). Scale bars: 100 μm
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in accord with previous studies showing that human and
murine SOD1s do not coaggregate [5, 21].
Equal degrees of ER stress in terminal hSOD1G127X mice
and hSOD1G127X/Becn1+/- mice
Endoplasmic reticulum (ER) stress, a condition in which
misfolded proteins accumulate in the lumen of the ER,
has been implicated in the pathogenesis of mutant
hSOD1 mouse models and ALS patients [3]. We ana-
lyzed the ER stress markers Grp78 and Chop, and found in-
creases in terminally ill mice (Additional file 5: Figure S5).
The final degree of activation was equal, but the stage ana-
lyzed appeared earlier in hSOD1G127X/Becn1+/- mice than
in hSOD1G127X mice.
Exacerbated disease also in hSOD1G93A/Becn1+/- mice
Mice that express G93A mutant hSOD1 are the most
commonly examined murine ALS model [23]. The model
is aggressive, with early onset of symptoms and a short
lifespan. The concentration of mutant hSOD1 is 17-fold
higher than that of the endogenous murine SOD1, causing
overexpression artifacts [4, 29]. Moreover, over 95 % of
the protein is natively folded, making analysis of misfolded
hSOD1 conformers complicated [54, 55]. For reference
purposes, we performed a limited study of the effects of
Becn1 deletion using this model (Fig. 6).
The time of onset was not significantly different in
hSOD1G93A mice and hSOD1G93A/Becn1+/- mice (121 ±
3.6 days vs. 125 ± 2.7 days; P = 0.23; Fig. 6a). However, the
disease duration was much shorter (52 ± 4.8 days vs. 31 ±
4.6 days; P = 5.7 × 10-9; Fig. 6b), leading to shortened sur-
vival (173 ± 5.7 days vs. 156 ± 4.6 days; P = 2.0 × 10-4;
Fig. 6a).
As with the hSOD1G127X model, the amount of aggre-
gated hSOD1 was higher in hSOD1G93A/Becn1+/- mice
than in hSOD1G93A mice at both the symptomatic stage
and the terminal stage (Fig. 6c, d, f ). In contrast to the
hSOD1G127X mice, no changes could be discerned in the
huge amounts of total and soluble hSOD1G93A mutant
present in the spinal cords (Fig. 6e).
Other changes were generally comparable to those in
hSOD1G127X/Becn1+/- mice, including autophagy factors,
lysosomal markers, murine SOD1 expression, and ER
stress markers (Additional file 4: Figure S4, Additional
file 5: Figure S5 and Additional file 6: Figure S6).
Larger increases in ubiquitinated insoluble proteins in
hSOD1G93A mice than in hSOD1G127X mice
The proteasome is the main pathway for degradation of
ubiquitinated proteins. However, autophagy also has a
role in the clearance of such proteins [46]. We thus
quantified the amounts of ubiquitinated insoluble pro-
teins (Fig. 7). The heterozygous deletion of Becn1 did
not in itself increase the concentration. In terminally ill
hSOD1G127X and hSOD1G93A mice, the levels were sig-
nificantly increased, and these increases were enhanced
by the Becn1 deletion (Fig. 7c, d). Remarkably, irrespect-
ive of Beclin 1 status, the increases were more than
double as high in hSOD1G93A mice as in hSOD1G127X
mice (Fig. 7a, b). The increases are not explained by im-
pairments of the proteolytic activities of the proteasome
(Additional file 7: Figure S7).
Discussion
A main finding in the present study was the low Beclin 1
concentration in lamina IX of the spinal ventral horns
from the two control groups. The other gray matter areas
examined, including the dorsal horns, contained around
seven times more Beclin 1 and, overall, they were similar
to each other. In accord with the low Beclin 1 levels, there
were also remarkably low concentrations of the down-
stream autophagy factors the Atg12-Atg5 complex, LC3-II
and p62. The motor neuron demise caused by mutant
SOD1 is partly non-cell autonomous since it is influenced
by the presence of the mutant protein also in the sur-
rounding glia [26]. Motor neuron somata and neurites
have been estimated to occupy 20 % of the volume of the
ventral horns [11], and together with supporting glia, they
should account for a major proportion of the specimens
analyzed here. Thus, low levels of autophagy factors
should be a characteristic of the cells that form the spinal
motor system. The cortical upper motor neurons are
sparse in the gray matter of the precentral gyrus, and they
would occupy a minor proportion of the volume. Thus,
we cannot draw any firm conclusions regarding the au-
tophagy capacity of the cells that form the upper motor
system.
(See figure on previous page.)
Fig. 5 Impaired autophagy increases hSOD1G127X aggregation, and reduces the amount of soluble species throughout the disease course. The spinal
cords (n = 5 per genotype per disease stage) were separated into three distinct fractions based on detergent solubility: whole homogenates,
detergent-insoluble, and detergent-soluble fraction. a Western blots for hSOD1G127X protein in the three fractions. β-Actin in whole homogenates was
used as a loading control. b-d Amounts of (b) total, (c) insoluble, and (d) soluble hSOD1G127X protein. *P < 0.05 vs. hSOD1G127X mice at 150 days of
age. **P < 0.01 vs. disease stage-matched hSOD1G127X mice (one-way ANOVA with Tukey-Kramer’s test). e Upper: Filter-trapped hSOD1G127X aggregates
in the spinal cords of the mice (n = 5 per genotype per disease stage). Lower: Amounts of hSOD1G127X aggregates. *P < 0.05 vs. hSOD1G127X mice at
150 days of age. **P < 0.01 vs. disease stage-matched hSOD1G127X mice (one-way ANOVA with Tukey-Kramer’s test). f Immunohistochemistry for
hSOD1G127X protein in lumbar spinal cords of mice. Scale bars: 100 μm
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In the ALS patients, there was evidence of some acti-
vation of autophagy, both in the ventral horns and in the
precentral gyrus. Notably, the subgroup carrying SOD1
mutations showed the greatest changes in the spinal
ventral horns, whereas the increases in the precentral
gyrus were more comparable in all ALS forms. This is in
accord with the lower motor neuron emphasis in ALS
patients with SOD1 mutations [2]. Despite the increases
in the autophagy initiator Beclin 1 and the Atg12-Atg5
complex, there was no evidence of autophagy activation
in terms of LC3-II elevations. Furthermore, the adaptor
protein p62, which is degraded together with protein ag-
gregates in autolysosomes [32], was accumulated, sug-
gesting that the autophagic flux might be impeded in
ALS. Thus, our findings might indicate a degree of
autophagy dysfunction, particularly in mutant SOD1-
induced ALS.
Inclusions containing misfolded SOD1 are found in not
only patients carrying SOD1 mutations, but also in both
sporadic and familial cases that carry other ALS-linked
mutant proteins [8, 16, 17, 21]. This suggests that the pro-
tein may be more generally involved in ALS. In this re-
gard, it is noteworthy that the granular SOD1 inclusions
within motor neurons of SALS patients colocalized par-
tially with lysosomal markers [17], which supports the
present evidence of dysregulation of autophagy in the
disease.
We found here that a moderate reduction in autoph-
agy by Becn1+/- caused more aggressive disease in
hSOD1G127X ALS model mice. There was earlier onset,
faster progression, and a markedly shortened lifespan. In
accord with the accelerated disease course, there was
also an earlier and more extensive loss of motor neu-
rons. It is notable that in the terminal stage the loss was
greater in the double mutant mice than in the
hSOD1G127X mice. It has been found that paralysis can
be caused by both loss of motor neurons and dysfunc-
tion of remaining motor neurons [20]. Perhaps the latter
mechanism played a proportionally greater role in the
hSOD1G127X mice. In parallel, an enhanced aggregation
of hSOD1G127X was found, showing the importance of
autophagy in elimination of protein aggregates. In con-
trast, the concentration of soluble hSOD1G127X, which
exists entirely as misfolded monomers [54, 55], was
lower from the presymptomatic stage to the end stage.
This is not explained by alterations in the proteasome,
which is the primary system for degradation of mis-
folded proteins: the activity did not change during the
course of the disease, and did not differ between the two
mouse types. Nor do the alterations seem to stem from
any changes in synthesis of SOD1 in compromised
spinal cord: the concentration of the endogenous murine
SOD1 was constant throughout the course of disease.
Autophagy is thought to be responsible for turnover of
long-lived proteins in the cytosol, but it apparently has
no significant role in degradation of murine SOD1,
which has a comparatively long half-life of 20 days in
the CNS [42]. We propose that the lower concentrations
of soluble misfolded hSOD1G127X in the hSOD1G127X/
Becn1+/- mice result from high rates of recruitment into
free fibril edges in the abundant hSOD1 aggregates (this
is discussed in supplementary data in [35]). The findings
are compatible with the notion that soluble, misfolded
SOD1 species provoke ALS through formation of aggre-
gates rather than through direct effects on critical com-
ponents in motor-area cells. Whether this conclusion
would hold for all ALS-linked SOD1 mutants is un-
known, but in our view it is more likely that they all
cause the disease by the same basic mechanism rather
than through several individual ones.
Beclin 1 exerts its role in autophagy induction by be-
ing a membrane-bound scaffold which enables the re-
cruitment of other autophagy proteins involved in
nucleation and maturation of the autophagosome [12].
By binding to various specific proteins, Beclin can also
localize to and regulate other vesicle trafficking pathways
[37]. Weakening of these may have contributed to the
phenotypes observed in the Becn1+/- mice. Retromer
trafficking is impaired in such mice leading to reduced
phagocytosis of extracellular aggregates by microglia
[36]. This may have contributed to the greater aggre-
gate accumulation in the hSOD1 transgenic mice with
the heterozygous Becn1 deletion than in those without
when compared at the same disease stages. Via binding
to the UV radiation resistance-associated gene protein
(UVRAG), Beclin 1 can localize to and regulate various
endocytic pathways, and this function is important for
the integrity of neurons [38]. Conditional Becn1
(See figure on previous page.)
Fig. 6 Heterozygous deletion of Becn1 in hSOD1G93A mice enhances aggregation and shortens survival. a Kaplan-Meier curves for disease onset
and survival of hSOD1G93A (n = 9; male:female 5:4) and hSOD1G93A/Becn1+/- mice (n = 12; male:female 7:5). b Scatter plot for disease duration. Bars
represents the mean values. **P < 0.01 (two-tailed Welch’s t-test). c Western blots for hSOD1G93A in whole homogenates, detergent-insoluble, and
detergent-soluble fractions extracted from the spinal cords (n = 4 per genotype per disease stage). β-Actin in whole homogenates was used as a
loading control. Amounts of (d) insoluble and (e) soluble hSOD1G93A protein. **P < 0.01 vs. disease stage-matched hSOD1G93A mice; N.S.: not
significant vs. disease stage-matched hSOD1G93A (one-way ANOVA with Tukey-Kramer’s test). f Upper: Filter-trapped hSOD1G93A aggregates in the
spinal cords of the mice (n = 4 per genotype per disease stage). Lower: Amounts of hSOD1G93A aggregates. **P < 0.01 vs. disease stage-matched
hSOD1G93A (one-way ANOVA with Tukey-Kramer’s test)
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knockout in neurons leads to impairment of endocytic
pathways and accelerated neurodegeneration [38]. The
degree of such impairment in mice with a heterozygous
Becn1 deletion is not known, but we cannot exclude
some role in the exacerbated phenotypes of the present
double mutant mice.
Fig. 7 More accumulation of insoluble ubiquitinated proteins in hSOD1G93A than hSOD1G127X mice. a Western blots for ubiquitinated proteins in
detergent-insoluble fractions extracted from the spinal cords of terminally ill mice and their littermates (n = 3 per genotype). β-Actin in whole
homogenate was used as an internal marker. b Densitometric calculations of the relative expression levels of ubiquitinated insoluble proteins in
various mouse genotypes. Data are given as mean ± SD. **P < 0.01 vs. hSOD1G127X. ##P < 0.01 vs. hSOD1G127X/Becn1+/- (one-way ANOVA with
Tukey-Kramer’s test). Temporal changes of ubiquitinated insoluble proteins in either (c) hSOD1G127X/Becn1+/- mice and littermates (n = 3–5 per
genotype) or (d) hSOD1G93A/Becn1+/- mice and littermates (n = 4 per genotype). **P < 0.01 vs. disease stage-matched hSOD1G127X. ##P < 0.01 vs.
disease stage-matched hSOD1G93A. N.S. not significant vs. 150-day-old hSOD1G127X (one-way ANOVA with Tukey-Kramer’s test)
Tokuda et al. Acta Neuropathologica Communications  (2016) 4:6 Page 15 of 18
A further potential confounding mechanism is the
binding of Beclin-1 to the antiapoptotic factors Bcl-2
and Bcl-XL in the ER. Beclin 1 is inactive when present
in such complexes and to exert its activities it has to be
released, which can be accomplished by a variety of
mechanisms [40]. The complex formation does, how-
ever, not seem to interfere with the activity of the antia-
poptotic factors, and there is no convincing evidence
that Beclin 1 can serve as a proapoptotic factor [13, 47].
Thus, it would appear less likely that any reduced cross-
talk with the apoptotic system influenced the disease in
the hSOD1G127X/Becn1+/- mice.
The results in the hSOD1G127X/Becn1+/- mice were
corroborated in the more aggressive hSOD1G93A model,
although the effects of the heterozygous Becn1 deletion
were smaller. The Becn1 deletion was even recently re-
ported to amend the disease in mice expressing G86R
mutant murine SOD1 [39]. Curiously, there was a non-
significant delay in onset of symptoms, but a shortened
symptomatic phase, together resulting in a 14-day pro-
longation of survival. Perhaps the Becn1 deletion by
some mechanism delayed the initiation of the murine
SOD1G86R aggregation, but still reduced the clearance of
aggregates once the process was under way. The unex-
pected result may also be related to the fact that this
transgenic model is even more aggressive than the
hSOD1G93A model. We found much greater increases in
ubiquitinated insoluble proteins in the hSOD1G93A
model than in the hSOD1G127X model. Part of the in-
creases might be related to increased accumulation p62
owing to autophagy inhibition. Such increased p62 has
been shown to inhibit delivery of substrate to the prote-
asome [33]. The increases in p62 were, however, com-
parable in the hSOD1G93A and hSOD1G127X models.
Perhaps a greater load of aggregated proteins in the
highly aggressive models leads to insufficiency in autoly-
sosomal clearance [7]. In that situation, a high degree of
autophagy flux might have negative effects, e.g. by en-
hancing lysosomal membrane destabilization [9]. Other
explanations for the discrepancy could be that the
SOD1G86R mutant was murine and that it also affected
another segment of the SOD1 protein. Thus, it cannot
be excluded that the consequences of altering Beclin-1
levels and autophagic capacity may differ between both
mouse models and different ALS patients.
The current findings may also shed light on the vul-
nerability of the motor system to mutations in other ubi-
quitously expressed proteins. Thus, mutations in VCP,
OPTN, UBQLN2, CHMP2B, SQSTM1/p62, DCTN1 [43],
TBK1 [14, 18] have all been suggested to cause impair-
ment of the autophagy-lysosomal system [24]. Mutations
in TARDBP, FUS, and C9orf72 are all associated with po-
tentially toxic protein aggregation [24]. Although the
anatomical conditions only allowed assessment of the
spinal motor system, the inherent low autophagy activity
detected might contribute to the selective vulnerability
both to aggregation-prone proteins and to mutations
that further depress the autophagy-lysosomal pathway.
Conclusions
The results of the study suggest that an inherent low au-
tophagy capacity might cause the selective vulnerability of
the motor system to mutant SOD1s, and that aggregation of
the protein plays a crucial role in the pathogenesis. The find-
ings may also explain the vulnerability to mutations in other
proteins expected to weaken the autophagy-lysosomal path-
way. This suggests that measures aimed at enhancing this
pathway might be beneficial in treatment of ALS. The inter-
ventions which have been tested so far in preclinical systems
and in patients have, however, yielded ambiguous results –
perhaps calling for development of new concepts [52].
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